A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors (IMAG1NE)

• ClinicalTrials.gov Identifier: NCT05430555
• Recruitment Status: Terminated
• First Posted: June 24, 2022
• Last Update Posted: February 7, 2024
• Sponsor: T-knife GmbH
• Information provided by (Responsible Party): T-knife GmbH

Tracking Information

• First Submitted Date: June 1, 2022
• First Posted Date: June 24, 2022
• Last Update Posted Date: February 7, 2024
• Actual Study Start Date: July 29, 2022
• Actual Primary Completion Date: January 8, 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 15, 2023)

• Safety and tolerability [ Time Frame: Up to 15 years after TK-8001 treatment (1 year short-term follow-up, 14 years long-term follow up) ]
  Incidence and grade of treatment-emergent adverse events (AEs) and serious adverse events (SAEs); Number and type of dose limiting toxicities (DLT)
• Preliminary anti tumor activity [ Time Frame: Up to 15 years after TK-8001 treatment, or until disease progression ]
  Evaluation of overall response rate (ORR), stable disease rate (SD), partial response rate (PR), and complete response (CR) rate of TK-8001 monotherapy, according to RECIST Version 1.1 and modified Response Evaluation Criteria in Solid Tumors (RECIST, V1.1) in cancer immunotherapy trials (iRECIST)

Original Primary Outcome Measures (submitted: June 23, 2022)

• Number of participants with treatment-emergent Adverse Events as assessed by CTCAE v5.0 (Part 1 of trial) [ Time Frame: Up to 15 years after TK-8001 treatment (52 weeks core follow-up, 14 years long-term follow up) ]
  Incidence and grade of treatment emergent adverse events and serious adverse events number and type of dose-limiting toxicities
• Antitumoral activity of TK-8001 (Part 2 of trial) [ Time Frame: Up to 15 years after TK-8001 treatment, or until disease progression ]
  Evaluation of overall response rate, rate of stable disease, partial response, and complete response rates of TK-8001 monotherapy, according to RECIST Version 1.1 and iRECIST

Current Secondary Outcome Measures (submitted: August 15, 2023)

End of dose escalation [ Time Frame: 28 days after TK-8001 treatment of last patient in Phase 1 ]

RP2D will be determined through integrated evaluation of adverse events, serious adverse events, antitumoral activity, and evaluation of the biological and physiological effects of TK-8001 in the body.

Original Secondary Outcome Measures (submitted: June 23, 2022)

End of dose escalation [ Time Frame: 28 days after TK-8001 treatment of last patient in part 1 ]

RP2D will be determined through integrated evaluation of adverse events, serious adverse events, antitumoral activity, and evaluation of the biological and physiological effects of TK-8001 in the body.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors
• Official Title: A Phase 1/2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 (MAGE-A1-Directed TCR-Transduced Autologous CD8+ T-cells) in Patients With HLA-A*02:01 Genotype and Advanced-Stage/Metastatic, MAGE-A1+ Solid Tumors That Either Have No Further Approved Therapeutic Alternative(s) or Are Not Eligible for Them or Are in a Non- Curable State and Have Received a Minimum of Two Lines of Systemic Therapy
• Brief Summary: The aim of this study is to determine the safety, tolerability and anti-tumoral activity of autologous T cells transduced with a T cell receptor specific for MAGE-A1 in eligible patients with advanced solid tumors.

Detailed Description

This is a Phase 1/2, first-in-human, open-label, accelerated titration, two-part clinical trial of TK-8001 (MAGE-A1-directed TCR-transduced autologous CD8+ T-cells) in subjects with HLA-A*02:01 genotype and advanced stage/metastatic, MAGE-A1+ solid tumors (including but not limited to melanoma [skin or uveal], NSCLC, urothelial, breast, gastric [including gastroesophageal junction], esophageal, sarcoma, HNSCC, HCC, biliary tract, cervical, and salivary gland cancer) that either have no further approved therapeutic alternative or are not eligible for them or that are in a non-curable state as per the Investigator's assessment and have received a minimum of two lines of systemic therapy.

This two-part clinical trial will consist of a Phase 1 Part, which includes dose-escalation and expansion, and a Phase 2 Part.

In the Phase 1 Part dose-escalation, at least 6 subjects and up to 18 subjects (if DLT occurs) will receive escalating doses of TK-8001, with up to three dose levels explored. During the Phase 1 Part expansion, up to 20 additional subjects may be treated on DL3 if cleared during dose escalation to further evaluate the safety and efficacy of TK-8001 (Cohort 1).

An additional cohort of up to 10 subjects with brain metastases (Cohort 2) may also be treated on DL3 if cleared during dose-escalation. The maximum total number of subjects to be treated on DL3 during Phase 1 will be 33 subjects.

In the Phase 2 Part, up to 30 patients will receive TK-8001 to further evaluate the efficacy and safety of TK-8001 and to confirm the RP2D.

Both the Phase 1 Part and Phase 2 Part of the trial will consist of the following periods: Screening and Leukapheresis Period, Conditioning Period, TK-8001 Treatment Period, DLT Monitoring Period, Short-term Follow-up Period (Year 1), and Long-term Follow-up Period (Year 2 - 15).

• Study Type: Interventional
• Study Phase: Phase 1; Phase 2

Study Design

Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description:

This 2-part trial consists of Phase 1 dose-escalation and expansion and Phase 2. In escalation, 6-18 subjects will receive TK-8001 across 3 dose levels (DL). In expansion, subjects will be treated with the DL selected in escalation. Subjects without brain metastasis (Cohort 1) and subjects with brain metastases (Cohort 2) will both be included in expansion if DL3 is declared safe. Cohort 1 will include melanoma [skin or uveal], NSCLC, urothelial, breast, gastric esophageal, sarcoma, HNSCC, HCC, biliary tract, cervical, and salivary gland cancer subjects. Cohort 2 will only include melanoma [skin or uveal], NSCLC, urothelial, or breast cancer. In expansion, up to 20 additional subjects may be treated on DL3 if cleared during escalation. Up to 10 additional Cohort 2 subjects may be treated on DL3 if cleared during escalation. 33 subjects maximum may be treated on DL3 during Phase 1. If DL2 was safely completed the maximum total number of subjects to be treated on DL2 would be 12.

Masking: None (Open Label)
Primary Purpose: Treatment

• Condition: Advanced Solid Tumors

Intervention

Biological: Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR

Single-dose intravenous infusion of MAGE-A1 directed TCR-transgenic T cells following a conditioning chemotherapy

Study Arms

Experimental: MAGE-A1 - directed TCR transduced autologous T-cells

Single-dose, intravenous infusion

Intervention: Biological: Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Terminated
• Actual Enrollment (submitted: February 5, 2024): 23
• Original Estimated Enrollment (submitted: June 23, 2022): 48
• Actual Study Completion Date: January 8, 2024
• Actual Primary Completion Date: January 8, 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Able to understand and comply with study procedures
• At least 18 years old
• Phase 1 Part dose-escalation and Phase 1 Part expansion Cohort 1 only: Presence of an advanced-stage/metastatic, solid tumor in non-curable state as per current medical knowledge, for which there is either no further approved therapeutic alternative available or the subject is not eligible for them or, for which the subject has completed a minimum of two lines of approved systemic therapy in the advanced-stage/metastatic setting.
• Phase 1 Part expansion Cohort 2 only: Presence of an advanced-stage/metastatic disease of the following indications: melanoma (skin or uveal), NSCLC, urothelial, breast cancer in non-curable state as per current medical knowledge, for which there is either no further approved therapeutic alternative available or the subject is not eligible for them or, for which the subject has completed a minimum of two lines of approved systemic therapy in the advanced-stage/metastatic setting.
• HLA-A*02:01 genotype.
• MAGE-A1+ tumor positive for MAGE-A1
• At least one measurable lesion, that can be accurately measured as per RECIST Version 1.1
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
• Life expectancy > 3 months as assessed by the Investigator
• All toxicities related to prior therapy must have recovered to baseline or Grade ≤ 1 based on CTCAE v5.0
• Immune-related adverse events (irAEs) from previous therapies must have recovered to baseline or Grade ≤ 1

Exclusion Criteria:

• Any tumor-directed therapy within 14 days before start of conditioning therapy
• Any other MAGE-A1-targeting therapy.
• Pre-existing arrhythmia, uncontrolled angina pectoris, presently uncontrolled heart failure, or any myocardial infarction/coronary event as well as any thromboembolic event at any time < 6 months prior to screening.
• Left ventricular ejection fraction (LVEF) < 45% as measured by an echocardiogram
• History of CNS disease such as stroke, seizure, encephalitis, or multiple sclerosis (within 6 months prior to screening)
• Active allergy requiring continuous systemic medication or active infections requiring IV/PO anti-infectious therapy
• History of or clinical evidence of CNS primary tumors or metastases, unless they have been previously treated, and have been stable for at least 4 weeks prior to trial entry
• Major surgery within last 4 weeks prior to consent
• Active disease/ongoing infection with HIV, HBV, HCV, TB, syphilis, or SARS-CoV-2
• Receipt of any organ transplantation, except for transplants that do not require immunosuppression
• Any vaccine administration within 4 weeks of IP administration.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Belgium, Germany, Netherlands, Spain, United Kingdom

Administrative Information

• NCT Number: NCT05430555
• Other Study ID Numbers: TK-8001-01; 2021-004158-49 ( EudraCT Number )
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: T-knife GmbH
• Original Responsible Party: Same as current
• Current Study Sponsor: T-knife GmbH
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Behzad K Masouleh, MD, PhD; T-knife GmbH

• PRS Account: T-knife GmbH
• Verification Date: February 2024